Concepedia

Biosimilar Affordability

Biosimilar Affordability is a pharmaceutical economic construct that denotes the degree to which biosimilar medications—highly similar versions of biologic reference products—are accessible and cost-effective for patients, healthcare systems, and payers, distinguished from broader medication affordability by its specific focus on the economic, regulatory, and market dynamics influencing the adoption and equitable access to biosimilars.

20

Publications

693

Citations

115

Authors

72

Institutions

Publications per year

2017–2026

16

Parents

Publications

20

The State of the Art in the Development of Biosimilars

Mark McCamish, Gillian R. Woollett · Clinical Pharmacology & Therapeutics · 2012 · 156 citations

, , +15

Rationale, Opportunities, and Reality of Biosimilar Medications

Gary H. Lyman, Robin Zoň, R. Donald Harvey et al. · New England Journal of Medicine · 2018 · 68 citations

, , +16

Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK

Mohammed Aladul, R Fitzpatrick, Stephen Chapman · BioDrugs · 2017 · 66 citations · Full text

, , +16

Drug Regulation and Pricing — Can Regulators Influence Affordability?

Hans‐Georg Eichler, Hugo Hurts, Karl Broich et al. · New England Journal of Medicine · 2016 · 48 citations

, , +17

Biosimilars: A Multidisciplinary Perspective

Majed Khraishi, David Stead, Milan Lukáš et al. · Clinical Therapeutics · 2016 · 45 citations

, , +15

1–5 of 20

Authors

115

  1. SS
    Steven Simoens

    KU Leuven, Belgium

    3 publications · 44 citations

    3

    h-index

  2. EA
    Eleonora Allocati

    Istituti di Ricovero e Cura a Carattere Scientifico, Italy

    2 publications · 33 citations

    2

    h-index

  3. GR
    Gillian R. Woollett

    Prevea Health, United States

    2 publications · 182 citations

    2

    h-index

  4. BG
    Brian Godman

    University of Strathclyde, United Kingdom

    2 publications · 33 citations

    2

    h-index

  5. AS
    Anurag S. Rathore

    Indian Institute of Technology Delhi, India

    2 publications · 28 citations

    2

    h-index

1–5 of 115

Institutions

72

  1. KU Leuven

    Leuven, Belgium

    3 h-index

    21 publications

    404 citations

  2. Karolinska Institutet

    Stockholm, Sweden

    2 h-index

    2 publications

    35 citations

  3. University of Strathclyde

    Glasgow, United Kingdom

    2 h-index

    3 publications

    55 citations

  4. Universiti Sains Malaysia

    George Town, Malaysia

    2 h-index

    2 publications

    33 citations

  5. Istituti di Ricovero e Cura a Carattere Scientifico

    Rome, Italy

    2 h-index

    2 publications

    33 citations

  6. Sefako Makgatho Health Sciences University

    Pretoria, South Africa

    2 h-index

    3 publications

    55 citations

  7. Indian Institute of Technology Delhi

    New Delhi, India

    2 h-index

    5 publications

    72 citations

  8. Mario Negri Institute for Pharmacological Research

    Milan, Italy

    2 h-index

    2 publications

    33 citations

1–8 of 72

Venues

  1. BioDrugs

    3 publications · 108 citations

    3

    h-index

  2. New England Journal of Medicine

    NEJM · 2 publications · 116 citations

    2

    h-index

  3. Generics and Biosimilars Initiative Journal

    1 publications · 23 citations

    1

    h-index

  4. Expert Opinion on Biological Therapy

    1 publications · 16 citations

    1

    h-index

  5. Current Medical Research and Opinion

    CMRO · 1 publications · 22 citations

    1

    h-index

1–5